NovaBay Pharmaceuticals (NYSE:NBY) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research note issued to investors on Tuesday. The brokerage issued a hold rating on the stock.

NovaBay Pharmaceuticals Price Performance

NovaBay Pharmaceuticals stock opened at $0.61 on Tuesday. NovaBay Pharmaceuticals has a 12-month low of $0.36 and a 12-month high of $9.08. The stock has a market capitalization of $3.54 million, a PE ratio of -0.01 and a beta of 0.73. The firm has a 50 day simple moving average of $0.65 and a 200-day simple moving average of $0.63.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.